William Dahms, DO
Nephrology · Newark, DENPI 1952419376
Payments from drug & device makers
Across 519 payments — averaging $181.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$36K
- Amgen$28K
- Bayer$13K
- Fresenius USA Marketing, Inc.$9K
- Otsuka America Pharmaceutical, Inc.$3K
- Mallinckrodt Hospital Products Inc.$981
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 61 | $36,455 |
| Amgen(2 entities) | 108 | $28,366 |
| Bayer | 41 | $12,576 |
| Fresenius USA Marketing, Inc. | 61 | $9,045 |
| Otsuka America Pharmaceutical, Inc. | 27 | $2,614 |
| Mallinckrodt Hospital Products Inc. | 31 | $981 |
| AstraZeneca(2 entities) | 32 | $647 |
| Calliditas Therapeutics US Inc. | 18 | $424 |
| Ardelyx, Inc. | 14 | $349 |
| Aurinia Pharma U.S., Inc. | 15 | $324 |
| Daiichi Sankyo Inc. | 12 | $210 |
| Novartis | 6 | $195 |
| Travere Therapeutics, Inc. | 11 | $192 |
| OPKO Pharmaceuticals, LLC | 11 | $190 |
| Akebia Therapeutics Inc | 8 | $176 |
| Lilly USA, LLC | 3 | $164 |
| Boston Scientific | 8 | $149 |
| Boehringer Ingelheim | 9 | $145 |
| Kyowa Kirin, Inc. | 6 | $115 |
| ANI Pharmaceuticals, Inc. | 4 | $109 |
| Sanofi | 5 | $92 |
| Medtronic | 1 | $85 |
| GSK | 5 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Shield Therapeutics Inc | 1 | $55 |
| AMAG Pharmaceuticals, Inc. | 3 | $43 |
| Nxstage Medical, Inc. | 1 | $39 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Shire North American Group Inc | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $33 |
| Bard Peripheral Vascular, Inc. | 2 | $25 |
| Genentech USA, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Surmodics, Inc. | 3 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Daxor Corporation | 1 | $10 |
How this compares
$94,090 in reported general payments places this provider in the 95th percentile of 49 nephrology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Newark
- Theodore SaadNewark$696K
- Prayus TailorNewark$127K
- Nealanjon DasNewark$6K
- Manthodi FaisalNewark$6K
- Piyaporn ApivatanagulNewark$5K
- Lindsey SlaterNewark$4K
- Christopher CanfieldNewark$3K
- Farhana ChowdhuryNewark$3K
- Feroz Abubacker KaniyamparambilNewark$3K
- Carlos MachadoNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.